EIP
MCRB icon

Ellis Investment Partners’s Seres Therapeutics MCRB Stock Holding History

Ellis Investment Partners’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14
Closed -$6K – 790
2021
Q2 		$6K Hold
14
– – ﹤0.01% 672
2021
Q1 		$6K Buy
+14
New +$6.45K ﹤0.01% 643

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ellis Investment Partners's MCRB Position: Q3 2021 in Review

Ellis Investment Partners sold out of Seres Therapeutics (MCRB) in Q3 2021, closing a stake of 14 shares — an estimated $6K sold.

Ellis Investment Partners first reported a position in MCRB in Q1 2021 and held it in 2 quarters. The position peaked at $6K in Q2 2021. 133 funds tracked by Wall St. Rank hold MCRB as of Q3 2021.

  • Ellis Investment Partners reported no remaining Seres Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Ellis Investment Partners sold 14 Seres Therapeutics shares in Q3 2021, an estimated $6K.
  • Ellis Investment Partners first reported a position in Seres Therapeutics in Q1 2021 and held it in 2 quarters.
  • Ellis Investment Partners's Seres Therapeutics position peaked at $6K in Q2 2021.
  • 133 funds tracked by Wall St. Rank held Seres Therapeutics as of Q3 2021.

Based on Ellis Investment Partners's 13F filing for Q3 2021, filed 21 Oct 2021.